Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL5922921 | 0.95 | IDO1 (0.43) | IDO1AGXTALDH1A1MMP9MMP2 | |
| SCHEMBL1828939 | 0.83 | HDAC4 (0.48) | IDO1AGXTALDH1A1MMP9MMP2 | |
| SCHEMBL1624940 | 0.82 | AGXT (0.44) | IDO1AGXTALDH1A1MMP9MMP2 | |
| SCHEMBL13180669 | 0.82 | MEN1 (0.46) | IDO1ALDH1A1APPKMT2A | |
| SCHEMBL16276338 | 0.81 | MAOB (0.51) | ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL12387355 | 0.80 | PRSS1 (0.39) | ALDH1A1KMT2ASMN1; SMN2TSHRNPC1 | |
| SCHEMBL1827659 | 0.80 | IDO1 (0.44) | IDO1AGXTALDH1A1MMP9MMP2 | |
| SCHEMBL10551219 | 0.79 | ALDH1A1 (0.53) | IDO1AGXTALDH1A1MMP9MMP2 | |
| SCHEMBL2794510 | 0.79 | CA2 (0.49) | ALDH1A1KMT2ACYP3A4POLB | |
| SCHEMBL31750770 | 0.79 | CYP1A2 (0.54) | KMT2ASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634970-B1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | LAURUS LABS LTD (IN) | 2023-07-19 | — | — | EP | claimed |
| US-11046676-B2 | Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof | LAURUS LABS LIMITED (IN) | 2021-06-29 | — | — | US | claimed |
| US-20200131163-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | LAURUS LABS LIMITED (IN) | 2020-04-30 | — | — | US | claimed |
| EP-3634970-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | Laurus Labs Limited (IN) | 2020-04-15 | — | — | EP | claimed |
| WO-2018224957-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | LAURUS LABS LIMITED (IN) | 2018-12-13 | — | — | WO | claimed |
| EP-2106403-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM Pharma (CH) | 2009-10-07 | — | — | EP | claimed |
| WO-2008059035-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2008-05-22 | — | — | WO | claimed |
| WO-2008059307-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2008-05-22 | — | — | WO | claimed |
| EP-4724070-A2 | WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12528806-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-10-23 | — | — | US | disclosed |
| US-12421233-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4615840-A1 | INDAZOL SUBSTITUTED 1,2,5-THIADIAZOLIDIN DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE (PTPN2) FOR THE TREATMENT OF CANCER DISEASES | Bristol-Myers Squibb Company (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-09-11 | — | — | US | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| EP-0650492-A1 | REDUCING INFLAMMATION BY TIME DEPENDENT ADMINISTRATION OF OLIGOSACCHARIDES GLYCOSIDES RELATED TO BLOOD GROUP DETERMINANTS | ALBERTA RESEARCH COUNCIL (CA) | 1995-05-03 | — | — | EP | disclosed |
| EP-0591254-A1 | IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWIS?X AND LEWIS?A COMPOUNDS | GLYCOMED INCORPORATED (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993024505-A1 | REDUCING INFLAMMATION BY TIME DEPENDENT ADMINISTRATION OF OLIGOSACCHARIDES GLYCOSIDES RELATED TO BLOOD GROUP DETERMINANTS | ALBERTA RESEARCH COUNCIL (CA) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| WO-1992022564-A1 | IMMUNOSUPPRESSIVE AND TOLEROGENIC MODIFIED LEWISX AND LEWISA COMPOUNDS | ALBERTA RESEARCH COUNCIL (CA) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131163-A1 | NOVEL PROCESS FOR PREPARATION OF EMPAGLIFLOZIN OR ITS CO-CRYSTALS, SOLVATES AND THEIR POLYMORPHS THEREOF | SLC5A1, SLC5A2, DPP4 | IDO1 3098/4885AGXT 90/4885ALDH1A1 2860/4885 |
| US-12421233-B2 | WRN inhibitors | WRN, BLM, RECQL | IDO1 3387/4885AGXT 3282/4885ALDH1A1 3002/4885 |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | KEAP1, NFE2L2, TXNRD2 | IDO1 3493/4885AGXT 474/4885ALDH1A1 588/4885 |
| US-11046676-B2 | Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof | SLC5A2, SLC5A1, DPP4 | IDO1 2978/4885AGXT 102/4885ALDH1A1 2460/4885 |
| US-12528806-B2 | WRN inhibitors | WRN, RECQL, BLM | IDO1 2346/4885AGXT 3163/4885ALDH1A1 1817/4885 |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | NFE2L2, BPTF, KEAP1 | IDO1 3407/4885AGXT 280/4885ALDH1A1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.